Lymphoma Lymphomas are malignant tumors that originate in the lymphopoietic system. It is divided into two categories, Hodgkin and non-Hodgkin, according to different cellular components. It is one of the top ten malignant tumors in China. The incidence of lymphoma accounts for about 5/100,000 and the annual growth rate of incidence is 7.5%, which is one of the fastest growing malignant tumors at present. Clinical manifestations The main manifestations are painless lymph node enlargement, liver and spleen enlargement, and all tissues and organs of the body can be involved, accompanied by fever, night sweats, emaciation, itching and other systemic symptoms. Classification and staging According to the World Health Organization (WHO) lymphatic system tumor pathology classification standards, nearly 70 types of lymphomas are known, which are broadly divided into two categories: Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). In China, HL accounts for 9-10% and NHL accounts for about 90%. Staging Clinical staging is mainly based on the site or extent of lymph node area involvement, stage I,II,III,IV. Treatment Current lymphoma treatment is based on combination chemotherapy, which can be combined with the targeted therapy drug rituximab. Autologous hematopoietic stem cell transplantation may be considered for patients under 60 years of age who are moderate to high risk and can tolerate high dose chemotherapy. Allogeneic HSCT may also be considered in some young patients with relapse or bone marrow invasion. Adjuvant radiation therapy. The specific treatment modality is tailored to each patient’s situation.